All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. The House of the Dragon ...

One of the biggest new shows of 2026 finally arrives this week. “Game of Thrones” fans should not, however, expect more of the same from “A Knight of the Seven Kingdoms,” HBO’s second and latest ...

A Knight of the Seven Kingdoms is the latest Game of Thrones spin-off from HBO, but it’s a drastically different show compared to anything we’ve seen before. Based on The Hedge Knight, a series of ...

A lighter story about an itinerant sword-swinger cuts “Game of Thrones” down to small pleasures. By James Poniewozik James Poniewozik is the chief television critic of The New York Times. Say what you ...

This is read by an automated voice. Please report any issues or inconsistencies here. Cersei chose violence. Rhaenyra commandeered dragons. But the protagonist of HBO’s new “Game of Thrones” spinoff, ...

The real world is way worse than Westeros – so why not let this heartwarming underdog tale of a simple soul and his ethereal squire be your safe space ‘Bless their little cotton socks!” is not a ...

Will Knight is a senior writer for WIRED, covering artificial intelligence. He writes the AI Lab newsletter, a weekly dispatch from beyond the cutting edge of AI—sign up here. He was previously a ...

Add articles to your saved list and come back to them any time. Tennis finally joined the modern sporting world in 2025, allowing players to receive on-court coaching during matches – if desired. It’s ...

Protesters on the streets of Tehran in 1979. The scenes that have unfolded in Iran in recent weeks are incredible yet unnervingly familiar © Alain Mingam/Gamma-Rapho ...

Modern art has always been a battleground — and the highly influential Museum of Modern Art has been partisan since its inception. Architectural historian Patricio Del Real discusses two differing ...

Revolution Medicines stock was jumping again early Friday. This time it’s a report that pharma giant Merck is in talks to buy the cancer-drug biotech for up to $32 billion.

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.